As part of the latest consolidation in the life sciences industry, Klick Health, which is the largest independent company, has announced the acquisition of Oxford PharmaGenesis, a top-notch HealthScience communications consulting firm that is known to have a wealth of knowledge on science, medicine, and market access across Europe, North America, and Asia-Pacific. With this development, the medical affairs experience of Oxford PharmaGenesis will be combined with the commercial strength of Klick Health. The transaction significantly scales Klick’s global footprint to 12 offices and expands its team to include over 500 advanced degree holders, reinforcing its position as the world’s largest independent life sciences commercialization partner.
Also Read: Causaly and Microsoft Partner to Bridge Computation and Scientific Decision-Making in Life Sciences R&D
Highlighting the alignment of the two organizations, Leerom Segal, Klick’s Co-Founder and Chairman, stated, “We are beyond proud to join forces with Chris, Richard, and the entire team at Oxford PharmaGenesis as we focus on helping life sciences clients think holistically about how evidence, medical strategy, access considerations, and stakeholder engagement connect across the lifecycle with a scientific-to-commercial offering that unlocks the true potential of their innovations.” Expressing shared optimism, Oxford PharmaGenesis CEO Chris Winchester said, “At Oxford PharmaGenesis, we are always looking for ways to bring the very best to our clients and create outstanding opportunities for our people. Joining Klick Health will ensure that we remain at the cutting edge of HealthScience communications but, more importantly, our shared values ensure a bright future together.” Echoing this sentiment, COO Richard White added, “This is the story of two successful companies growing strongly by themselves, driven by a desire to give clients what they are going to need next, and realizing that we could achieve that better together.”
